InVenis Biotherapies
ABOUT US
InVenis Biotherapies is a biotechnology company, spin-off of the academic laboratory U1172 and Taipei Medical University, developing innovative regenerative therapies based on blood platelets. Thanks to the strong therapeutic potential of our product, we are targeting the most serious diseases leading to cell death, such as amyotrophic lateral sclerosis.
Therapeutic concept
Pharmacological neuromodulation
Growth factors (GFs) are natural molecules capable of stimulating cell growth, proliferation and differentiation. They are therefore ideal candidates for promoting cell survival.
The initial strategy of single growth factors failed due to lack of effectiveness. Stem cell transplantation is limited by significant environmental alteration. Their multiple secretome rich in GF can be effective but is not maintained over time due to rapid cell destruction. Platelets represent a powerful and natural healing system and contain an abundant source of physiological GF mixtures, which has been demonstrated in soft and hard tissue regenerative medicine.
Therefore, we are developing a new biotherapy based on human platelet lysates that can be continuously infused.